Core Insights - Jiangning High-tech Zone has significantly improved its competitiveness ranking, moving up 4 places to 13th in the 2024 National Biopharmaceutical Industry Park Competitiveness Ranking released at the 2025 China Biotechnology Innovation Conference [3][4] - The ranking is based on a comprehensive evaluation of various dimensions including environment, industry, technology, talent, and cooperation, aimed at promoting the development and transformation of China's biopharmaceutical industry clusters [3] Group 1: Industry Overview - Jiangning High-tech Zone is recognized as a key cluster for the biopharmaceutical industry in the Yangtze River Delta, positioning biopharmaceuticals as its primary industry for regional transformation [3] - The park has attracted nearly 400 pharmaceutical companies, covering six major sectors including new drug development, cell and gene therapy, and high-end medical devices [3] Group 2: Performance Metrics - In 2024, the park successfully listed two Class 1 innovative drugs, with the pharmaceutical industry's revenue growth exceeding 30%, leading the city [3] - By the beginning of 2025, Jiangsu Province's first Class 1 innovative drug was developed in this zone, with a nearly 40% revenue growth for the first three quarters of the year, showcasing the industry's explosive growth potential [3][4] Group 3: Strategic Focus Areas - Jiangning High-tech Zone is strategically focusing on four emerging sectors: cell and gene therapy, nuclear medicine, beauty and health, and brain-computer interfaces, employing a model of "leading enterprises + chain extension + ecosystem construction" to build a competitive industrial cluster [4] - In the cell and gene therapy sector, the zone has established a complete industrial chain from gene synthesis to commercial production, leveraging leading companies such as Genscript and Ruigen Biotech [4] - The nuclear medicine sector aims to create a comprehensive ecosystem in collaboration with GE Healthcare and Dongcheng Andico, focusing on the entire production chain from target discovery to clinical transformation [4]

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is currently under short-term pressure but has a rich pipeline of new products and is expected to benefit from a potential recovery in industry demand [1][5] - The completion of the acquisition of Korean Regen Company strengthens the company's leading position in the medical beauty injection market and expands its international market presence [2] - The company has received certification for its minoxidil topical solution, which is aimed at treating male pattern baldness, and has successfully registered its first new cosmetic ingredient [2][3] Financial Performance - In Q3 2025, the company reported revenue of 566 million yuan, a year-on-year decrease of 21.3%, and a net profit attributable to the parent company of 304 million yuan, down 34.6% [1][7] - For the first three quarters of 2025, total revenue was 1.865 billion yuan, down 21.5% year-on-year, with a net profit of 1.093 billion yuan, a decrease of 31.0% [1] Product Pipeline and Development - The company has a robust pipeline with products like second-generation implant lines and injectable botulinum toxin expected to enter the registration phase by the end of 2025 [3] - Clinical trials for new products are ongoing, and successful launches could create new growth points for the company [3] Margin and Cost Analysis - The gross margin in Q3 2025 was recorded at 93.2%, a decrease of 1.4 percentage points year-on-year [4] - The report notes an increase in sales and management expense ratios due to rising labor and consulting service costs [4] Earnings Forecast and Valuation - Revenue forecasts for 2025-2027 have been adjusted downwards to 2.424 billion, 2.796 billion, and 3.083 billion yuan, respectively [5] - The net profit forecasts for the same period have also been revised down to 1.391 billion, 1.670 billion, and 1.945 billion yuan [5] - The target price is set at 182.16 yuan, based on a 33x PE ratio for 2026 [5]